Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Subscribe to Free Drug Patent Expiration Updates

Also available in a Drug Patent Expiration NewsletterRSS feed and on Drug Patent Expirations on TwitterTwitter

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: NIMBEX

« Back to Dashboard
Nimbex is a drug marketed by Abbvie and is included in one NDA. It is available from one supplier.

The generic ingredient in NIMBEX is cisatracurium besylate. There are eight drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cisatracurium besylate profile page.

Summary for Tradename: NIMBEX

Suppliers / Packagers: see list3

Pharmacology for Tradename: NIMBEX

Clinical Trials for: NIMBEX

Optimal Dose of Combination of Rocuronium and Cisatracurium
Status: Completed Condition: Chronic Otitis Media; Anesthesia

Effects of Cisatracurium on Succinylcholine-induced Fasciculations and Myalgia
Status: Completed Condition: Fasciculation

Effect of Laparoscopic Operation on Rocuronium and Cisatracurium: Pharmacokinetic and Pharmacodynamic Analysis
Status: Not yet recruiting Condition: C.Delivery; Surgery (Previous), Gynecological

Study of Cisatracurium and Sufentanil Consumption Using a Closed Loop Computer Control Infusion System
Status: Recruiting Condition: The Intraoperative Effect of Dexmedetomidine on Cisatracurium Infusion Consumption and Its Recovery Index.; Effect of Dexmedetomidine on Sufentanil Consumption.; Quantitative Analysis of Cisatracurium Infusion Requirements, Sufentanil Consumption and Recovery Index in Different Age Groups.

Effects of Cisatracurium on Sccinylcholine-induced Fasciculations
Status: Not yet recruiting Condition: Fasciculations

Comparison of the Effects of Vecuronium and Cisatracurium on Electrophysiologic Monitoring During Neurosurgery
Status: Completed Condition: Motor Evoked Potential Monitoring; General Anesthesia; Neurosurgery; Brain Tumor; Spine Tumor; Cerebral Aneurysm

Comparison Between Cisatracurium and Rocuronium in Terms of Recovery of the Muscular Strength in the Postoperative Phase After Surgery and General Anaesthesia
Status: Completed Condition: Postoperative Residual Curarization; Residual Neuromuscular Block

Depth of Neuromuscular Blockade and the Perioperative Conditions in Laparoscopic Surgery in Pediatric Population
Status: Not yet recruiting Condition: Neuromuscular Blockade

Effect of Cisatracurium Versus Atracurium on Intraocular Pressure in Patients Underwent General Anesthesia
Status: Completed Condition: Intraocular Pressure

Appropriate Dose of Neostigmine for Reversal of Rocuronium and Cisatracurium
Status: Completed Condition: Observation of Neuromuscular Block

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
cisatracurium besylate
INJECTABLE;INJECTION020551-001Dec 15, 1995RXYes<disabled><disabled>
cisatracurium besylate
INJECTABLE;INJECTION020551-003Dec 15, 1995RXYes<disabled><disabled>
cisatracurium besylate
INJECTABLE;INJECTION020551-002Dec 15, 1995RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: NIMBEX

Drugname Dosage Strength RLD Submissiondate
cisatracurium besylate (multi-dose) Injection2 mg/mL, 10 mL vialNimbex8/12/2009
cisatracurium besylate (preserve free)Injection2 mg/mL, 5 mL vial and 10 mg/mL, 20 mL vialNimbex8/4/2009
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn